Biosimilar Integration: Administration’s Considerations
Webinar will be released on November 1, 2019.
Offered On-Demand only.
Statement of Need/Activity Purpose
This webinar will review the numerous financial, operational, and clinical aspects to consider when implementing biosimilars into oncology care.
- Review the approval and commercialization process of biosimilar medication
- Examine biosimilar’s impact on marketplace trends
- Review various financial, operational, and clinical considerations for the use of biosimilars
- Present methods to successfully incorporate biosimilars into oncology workflow
Philip Schwieterman, PharmD MHA
Philip Schwieterman obtained his bachelors and doctorate of pharmacy degrees from The Ohio State University and his Master of Health Administration from the University of Kentucky. Philip joined UK HealthCare as a Pharmacy Director in 2013 where he has led numerous financial, clinical, and operational initiatives surrounding the growth and oversight of oncology, infusion, specialty and pediatric pharmacy services. He currently serves as the Pharmacy Director for Oncology and Pediatrics.
This activity is intended for Hematology/Oncology pharmacists. This activity has been approved for 1.00 contact hours (.10CEUs) under the ACPE universal activity number # 0465-0000-19-098-H04-P.
HOPA Member ‒ $0
Nonmember ‒ $0
The Hematology/Oncology Pharmacy Association (HOPA) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. A statement of credit will be issued only upon completion of the post-activity evaluation form and post-test. ACPE credit must be claimed by October 25, 2022.
Supported by an independent medical education grant from Sandoz Inc., a Novartis Division.